MX2021007090A - Producto del compuesto activo {4,6-diamino-2-[5-fluoro-1-(2-fluoro bencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo que tiene propiedades mejoradas, produccion y formulacion del mismo. - Google Patents

Producto del compuesto activo {4,6-diamino-2-[5-fluoro-1-(2-fluoro bencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo que tiene propiedades mejoradas, produccion y formulacion del mismo.

Info

Publication number
MX2021007090A
MX2021007090A MX2021007090A MX2021007090A MX2021007090A MX 2021007090 A MX2021007090 A MX 2021007090A MX 2021007090 A MX2021007090 A MX 2021007090A MX 2021007090 A MX2021007090 A MX 2021007090A MX 2021007090 A MX2021007090 A MX 2021007090A
Authority
MX
Mexico
Prior art keywords
active compound
compound product
fluorobenzyl
pyrazolo
pyrimidin
Prior art date
Application number
MX2021007090A
Other languages
English (en)
Inventor
Peter Fey
Heike Neumann
Guido Becker
Michal Sowa
Markus Longerich
Joerg Brockob
Original Assignee
Adverio Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adverio Pharma Gmbh filed Critical Adverio Pharma Gmbh
Publication of MX2021007090A publication Critical patent/MX2021007090A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a {4,6-diamino-2-[5-fluoro-1-(2-f luorobencil)-1H-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbam ato de metilo en forma de un nuevo producto de sustancia activa con propiedades mejoradas, por ejemplo, con respecto a la capacidad de aislamiento del producto del principio activo, la capacidad de vertido del producto de la sustancia activa tras el aislamiento y el secado, así como la capacidad de transporte, cribado y micronización del producto de la sustancia activa, y los procesos para su fabricación y formulación.
MX2021007090A 2018-12-17 2019-12-16 Producto del compuesto activo {4,6-diamino-2-[5-fluoro-1-(2-fluoro bencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo que tiene propiedades mejoradas, produccion y formulacion del mismo. MX2021007090A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18213115 2018-12-17
PCT/EP2019/085255 WO2020126983A1 (en) 2018-12-17 2019-12-16 Methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate active compound product having improved properties, production and formulation thereof

Publications (1)

Publication Number Publication Date
MX2021007090A true MX2021007090A (es) 2021-08-11

Family

ID=64744472

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007090A MX2021007090A (es) 2018-12-17 2019-12-16 Producto del compuesto activo {4,6-diamino-2-[5-fluoro-1-(2-fluoro bencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo que tiene propiedades mejoradas, produccion y formulacion del mismo.

Country Status (18)

Country Link
US (1) US20220048907A1 (es)
EP (1) EP3898624A1 (es)
JP (1) JP2022515376A (es)
KR (1) KR20210104703A (es)
CN (1) CN113207290B (es)
AR (1) AR116912A1 (es)
AU (1) AU2019409269A1 (es)
BR (1) BR112021009122A2 (es)
CA (1) CA3123360A1 (es)
CL (1) CL2021001580A1 (es)
CO (1) CO2021007668A2 (es)
IL (1) IL283976A (es)
JO (1) JOP20210155A1 (es)
MX (1) MX2021007090A (es)
PE (1) PE20211593A1 (es)
SG (1) SG11202104953VA (es)
TW (1) TWI830835B (es)
WO (1) WO2020126983A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115175666B (zh) 2020-02-03 2024-04-26 阿德弗里奥药品有限责任公司 {4,6-二氨基-2-[5-氟-1-(2-氟苄基)-1H-吡唑并[3,4-b]吡啶-3-基]嘧啶-5-基}氨基甲酸甲酯的纳米制剂
EP3925953A1 (en) 2020-06-16 2021-12-22 Adverio Pharma GmbH Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2745813B1 (fr) 1996-03-07 1998-05-07 Rhone Poulenc Chimie Agglomerats spheriques d'acide 10-phenothiazinylpropanoique et leur procede de preparation
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
HUE041592T2 (hu) * 2011-11-25 2019-05-28 Adverio Pharma Gmbh Eljárás szubsztituált 5-fluor-1H-pirazolopiridinek elõállítására
AP2015008670A0 (en) * 2013-02-21 2015-08-31 Adverio Pharma Gmbh Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-B]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate
RS55673B1 (sr) 2013-04-19 2017-06-30 Zach System Postupak za dobijanje čvrstog oblika abirateron acetata
WO2016113415A1 (en) * 2015-01-16 2016-07-21 Sandoz Ag Process for the preparation of riociguat essentially free from genotoxic impurities
WO2017025981A1 (en) * 2015-08-13 2017-02-16 Msn Laboratories Private Limited Process for the preparation of methyl 4,6-diamino-2-[l-(2-fhiorobenzvr)-lh-pyrazolo i3,4-blpvridin-3-vn-5-pyrimidinyl(methvl)carbamate and its polymorphs thereof
CN115175666B (zh) * 2020-02-03 2024-04-26 阿德弗里奥药品有限责任公司 {4,6-二氨基-2-[5-氟-1-(2-氟苄基)-1H-吡唑并[3,4-b]吡啶-3-基]嘧啶-5-基}氨基甲酸甲酯的纳米制剂
EP3925953A1 (en) * 2020-06-16 2021-12-22 Adverio Pharma GmbH Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate

Also Published As

Publication number Publication date
CO2021007668A2 (es) 2021-07-19
CA3123360A1 (en) 2020-06-25
AU2019409269A1 (en) 2021-06-03
WO2020126983A1 (en) 2020-06-25
KR20210104703A (ko) 2021-08-25
US20220048907A1 (en) 2022-02-17
CN113207290B (zh) 2024-04-09
CN113207290A (zh) 2021-08-03
BR112021009122A2 (pt) 2021-08-10
SG11202104953VA (en) 2021-06-29
TW202039488A (zh) 2020-11-01
PE20211593A1 (es) 2021-08-18
CL2021001580A1 (es) 2021-12-03
JP2022515376A (ja) 2022-02-18
IL283976A (en) 2021-07-29
TWI830835B (zh) 2024-02-01
AR116912A1 (es) 2021-06-23
JOP20210155A1 (ar) 2023-01-30
EP3898624A1 (en) 2021-10-27

Similar Documents

Publication Publication Date Title
ECSP18018453A (es) Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificación para su uso como principio activo farmacéutico
MY194021A (en) 4-amino-2-(1hpyrazolo[3,4-b]pyridin-3-yl)-6-oxo-6,7-dihydro-5h-pyrrolo[2,3-d]pyrimidine derivatives and the respective (1h-indazol-3-yl) derivatives as cgmp modulators for treating cardiovascular diseases
EP3577116A4 (en) DERIVATIVES OF N-CYCLOALKYL / HETEROCYCLOALKYL-4- (IMIDAZO [1,2-A] PYRIDINE) PYRIMIDINE-2-AMINE AS THERAPEUTICS
MX2015009950A (es) Compuestos de imidazopiridina y sus usos.
PH12018501643A1 (en) Tlr7 agonist crystalline form a, preparation method and use thereof
PH12019500586A1 (en) Pyrazolo [1,5-a] pyridine derivatives and their use as pesticides
PH12017500111A1 (en) Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
MX2016012668A (es) Derivados de 4,5,6,7-tetrahidro-pirazolo[1,5-a]pirazina sustituidos y derivados de 5,6,7,8-tetrahidro-4h-pirazolo[1,5-a][1 ,4]diazepina como inhibidores de ros1.
PH12018501362A1 (en) Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
MX367913B (es) Derivados de 4,5,6,7-tetrahidro-pirazolo[1,5-a]pirimidina y 2,3-dihidro-1h-imidazo[1,2-b]pirazol sustituidos como inhibidores de ros1.
MY185491A (en) Macrocylic pyrimidine derivatives
MX2020005079A (es) Derivados de aminotiazol utiles como agentes antiviricos.
JOP20210155A1 (ar) منتج مركب نشط من {4، 6-ثنائي أمينو-2-[5-فلورو-1-(2-فلورو بنزيل)-1h-بيرازولو [3، 4-ب] بيريدين-3-يل] بيريميدين-5-يل} كربامات مثيل له خواص محسنة، إنتاجه وتركيبة منه
MY173573A (en) Pyridin-4-yl derivatives
MX367772B (es) Derivados de n-(2,3-dihidro-1h-pirrolo[2,3,b]piridin-5-il)-4-quina zolinamina y n-(2,3-dihidro-1h-indol-5-il)-4-quinazolinamina novedosos como inhibidores de perk.
MX2019012454A (es) Compuesto solido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol.
TN2012000258A1 (en) Novel polymorphic shapes of methyl{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridine-3-yl]pyrimidin-5-yl)carbamate
MX2020010834A (es) Formulacion solida de mezclas insecticidas.
WO2018193090A3 (en) METHOD FOR PREPARING ELIGLUSTAT HEMITARTRATE AND INTERMEDIATES THEREOF
MX2019011458A (es) Una coleccion de articulos absorbentes, especificos por genero, de tipo calzoncillo, desechables.
MX2018015707A (es) Derivados biciclicos de piridina, pirazina y pirimidina como inhibidores de pi3k beta.
GEP201706614B (en) Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
MX2020014124A (es) Preparacion de aptameros.
MY191218A (en) Agent for improving early insulin secretory capacity
MY197130A (en) Tlr7 agonist crystalline form a, preparation method and use thereof